PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32978718-0	2021	Esomeprazole inhibits the lysosomal cysteine protease legumain to prevent cancer metastasis.	Esomeprazole	0-12	legumain	Homo sapiens	54-62	
32978718-4	2021	In this study, we have identified esomeprazole and omeprazole as novel legumain small molecule inhibitors by screening an FDA approved-drug library.	Esomeprazole	34-46	legumain	Homo sapiens	71-79	
32978718-5	2021	These compounds inhibited enzyme activity of both recombinant and endogenous legumain proteins with esomeprazole displaying the highest inhibitory effect.	Esomeprazole	100-112	legumain	Homo sapiens	77-85	
32978718-6	2021	Further molecular docking analysis also indicated that esomeprazole, the S- form of omeprazole had the most stable binding to legumain protein compared to R-omeprazole.	Esomeprazole	55-67	legumain	Homo sapiens	126-134	
32978718-9	2021	These results indicated that esomeprazole has the exciting potential to be used in anti-cancer therapy by preventing cancer metastasis via the inhibition of legumain enzyme activity.	Esomeprazole	29-41	legumain	Homo sapiens	157-165